JNJ vs WMT: How Johnson & Johnson and Walmart Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and WMT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and WMT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Walmart is the largest retailer in the world by revenue and the biggest private employer in the United States. It runs more than 10,000 stores and clubs globally under the Walmart and Sam's Club banners, plus a large and fast-growing e-commerce and digital business. Its core proposition is everyday low prices on groceries and general merchandise, achieved through enormous purchasing scale and a highly efficient supply chain. Walmart makes most of its money from US grocery and general merchandise, but it is increasingly building higher-margin profit engines on top of that traffic: Walmart Connect (a retail advertising business), Walmart+ (a subscription membership), marketplace and fulfillment services for third-party sellers, and financial and health services. Roughly a quarter of revenue comes from outside the US, led by operations in Mexico (Walmex), China, and India (Flipkart). Headquartered in Bentonville, Arkansas, Walmart is a defensive, scale-driven retailer competing with Amazon, Costco, and Target.

Full WMT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• WMT drivers: Advertising and high-margin profit pools; Omnichannel scale and grocery dominance.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For WMT, walmart's core retail margins are thin, so it depends on enormous volume and on the new high-margin businesses scaling to lift profitability.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; WMT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and WMT guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

WMT. Walmart trades at a historically high P/E for a retailer, reflecting the market's enthusiasm for its higher-margin advertising, marketplace, and membership businesses layered on a defensive grocery base. The thin core margin means earnings growth depends heavily on these new profit pools scaling. Walmart is valued as a quality, recession-resilient compounder rather than a pure low-margin retailer.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; WMT shows revenue (ttm) ~$680 billion, operating margin ~4-4.5% (thin, by design), net income (ttm) ~$17-20 billion, eps (ttm) ~$2.30-2.60 adjusted.

JNJ and WMT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and WMT exposure against your real portfolio. It is not an investment adviser.